Previous studies of quality of life (QOL) note compromised QOL after stem cell transplantation (HCT), but do not usually consider the impact of pre-transplantation deficits in QOL on post transplantation outcomes. To examine these associations, multivariate models for six self-reported QOL outcomes at 6 and 12 months were constructed, considering pre-transplantation clinical status and QOL, and subsequent clinical events. Outcomes measured overall subjective health, social functioning and agreement with statements such as 'Life has returned to normal.' Of 320 autologous and allogeneic HCT recipients who completed pre-transplantation surveys, 197 completed 6-month surveys and 175 completed 12-month surveys. Pre-transplantation overall health and mental health were independent predictors of all QOL outcomes at 6 months. Baseline physical health was also predictive of four of six outcomes at 12 months. In contrast, disease risk was predictive only of enjoying normal activities at 6 months. Relapse and chronic graft-versus-host disease were associated with poorer QOL. In conclusion, pretransplantation self-reported physical and mental health are more strongly associated with QOL after HCT than commonly noted baseline clinical predictors such as age and disease risk. Measurement of baseline QOL can help place the effects of the transplantation procedure in context.
Introduction
Autologous and allogeneic hematopoietic stem cell transplantations (HCT) offer the potential to cure some hematologic malignancies. At the same time, the treatment-related toxicity can be quite high, and health problems resulting from the HCT as well as the underlying disease and prior therapy have a large impact on quality of life (QOL) and survival following transplantation.
There are an estimated 100 000 5-year survivors of HCT worldwide. 1 Observation of these patients has revealed a host of sequelae that impair QOL. These include medical problems such as chronic graft-versus-host disease (GVHD) and increased susceptibility to infection. Fatigue is a commonly reported symptom among survivors. 2 Psychological difficulties are also often present. Depression 3 and anxiety 4 are common, including a 5% incidence of post-traumatic stress disorder. 5 In one study, 22% of patients reported sexual dissatisfaction. 6 These and other medical and psychological difficulties have an impact on QOL.
Previous studies, many of them cross-sectional and retrospective, have identified biological factors and clinical events predicting poorer QOL outcomes, including older age, female gender and chronic GVHD. [7] [8] [9] Patients undergoing HCT all have a serious underlying medical problem, which is the reason for the HCT, and this baseline morbidity may impair QOL before the transplantation. It is not known how and to what degree, pre-transplantation QOL affects patients' QOL and subjective recovery after the transplantation. To answer these questions, we examined prospectively collected QOL data from a cohort of patients undergoing allogeneic and autologous HCT for hematologic malignancies. These patients had assessment of QOL before transplantation, utilizing both validated numerical scales and subjective assessments of overall health, and assessment of QOL after transplantation through subjective questions about recovery and social functioning. We hypothesized that both pre-transplantation characteristics (pre-existing QOL, disease risk) and post transplantation events (relapse, chronic GVHD) would influence QOL as measured among survivors of HCT.
Materials and methods

Patients
All patients over the age of 18 years undergoing autologous or allogeneic HCT at the Brigham and Women's Hospital (BWH) or Dana-Farber Cancer Institute (DFCI) were eligible for this study. Enrollment began at the BWH in August 1996 and at the DFCI in January 1997. Patients were contacted by phone to describe the study, then mailed questionnaires and a self-addressed, stamped envelope. Some patients could not be contacted before admission for transplantation because of logistical reasons. Others did not speak or read English. Others elected not to participate in the study or did not return pre-transplantation questionnaires and thus were not enrolled. Surviving patients were again mailed questionnaires at 6 and 12 months. The study protocol and materials were approved by the BWH and DFCI institutional review boards and all patients signed informed consent for participation.
Disease status was categorized at the time of study enrollment into three groups. Good risk was considered leukemia in first complete remission, stable-phase chronic myelogenous leukemia (CML), aplastic anemia or early (refractory anemia) myelodysplastic syndrome (MDS). Intermediate risk included leukemia in second or greater complete remission or untreated advanced myelodysplastic or myeloproliferative syndromes, or lymphoma or multiple myeloma with complete or partial response to chemotherapy. Poor risk diseases were considered refractory or in relapse.
Demographic information including age, sex, level of education and marital status was collected from the completed questionnaires. Information regarding diagnosis, type of transplant and incidence of clinical events such as acute and chronic GVHD and hematologic relapse were collected from the DFCI HCT database.
Physician and/or patient preference determined enrollment on specific treatment protocols. Allogeneic recipients generally were conditioned with cyclophosphamide and total body irradiation (TBI), or with busulfan and cyclophosphamide when TBI was contraindicated. Autologous recipients were conditioned with cyclophosphamide/ TBI, melphalan/TBI or cyclophosphamide/etoposide/carmustine. Graft-versus-host disease prophylaxis regimens were also varied and included methotrexate/cyclosporine7 corticosteroids, tacrolimus, cyclosporine/prednisone or Tcell depletion using an anti-CD6 antibody and complement. These transplant protocols have been published. [10] [11] [12] [13] [14] Quality of life instruments Patients were surveyed by mail before hospital admission and at 6 and 12 months post HCT. The survey solicited qualitative information on symptoms, self-assessment of health, feelings about the transplantation procedure and sense of recovery after transplantation. Patients who died before a time point or failed to return questionnaires were excluded from the analyses; none of their responses were imputed or assumed. A five-point scale was used to indicate overall health (excellent, very good, good, fair or poor) and agreement or disagreement with statements regarding recovery from transplant (e.g. 'I feel back to my old self,' 'Life has returned to normal') and social functioning (e.g. 'I am enjoying socializing with my friends and family after transplant'). For the purposes of the statistical analysis, responses to these questions were dichotomized into 'agree or strongly agree' versus 'somewhat agree, neutral or disagree.' Responses regarding overall health were dichotomized into 'excellent or very good' versus 'good, fair or poor. ' In addition to these constructed measures, patients completed the Short-Form 36 (SF-36) 15 at each point. The SF-36 is a generic health survey that provides information on general health status, including physical and mental functioning. The physical and mental composite scores (PCS and MCS) are normalized so that 50 represents the health status of the general population. The SF-36 was scored according to published guidelines with techniques for handling of missing data. Before transplantation, patients also completed a numerical health rating scale in which they indicated their state of health over the last 2 weeks. The scale ranged from 0 (dead) to 100 (perfect health).
Statistical analysis
Multivariate models (stepwise multiple linear and logistic regression) were constructed for each QOL outcome at 6 and 12 months to identify independent predictors.
The models included baseline clinical and QOL variables, as well as post transplant clinical events. Variables were entered into the baseline model in the following order: type of transplant, disease risk, occurrence of chronic GVHD, occurrence of relapse, self-reported overall health, selfreported numerical health rating scale, physical composite SF-36 score, mental composite SF-36 score, marital status, educational status, gender and age. The regressions were also repeated with the QOL variables entered first, followed by the clinical characteristics. The different ordering of the variables did not affect the results in any of the models. Grade II-IV acute and chronic GVHD were treated as dichotomous variables indicating presence or absence of the condition. The outcomes of interest were responses to the qualitative questions regarding overall health, recovery from HCT and social functioning at 6 and 12 months post transplantation. All variables with a P-value o0.1 were included in the model building. Predictors with a P-value p0.05 were considered statistically significant. Statistical analysis was performed with SAS for Windows version 8.2.
We elected to construct separate models for the two time points of interest, rather than using a repeated measures model, for several reasons. The development of chronic GVHD and disease relapse, which were essential to include in the model, are time-dependent covariates and cannot be included in a repeated measures model for technical reasons. Furthermore, our multivariate models allowed us to generate odds ratios to express the magnitude of the effect of each independent variable. Repeated measures models yield parameter estimates, which are less readily interpretable in terms of their clinical significance.
To determine independent predictors of overall survival (defined as death from any cause), a multivariate Cox proportional hazards regression model was constructed. The same predictor variables utilized in the models for QOL were used. The assumption of proportionality was tested for all covariates, and the final model was determined using a forward stepwise approach. Variables with a P-value p0.05 were considered statistically significant.
One-way repeated measures analysis of variance was used to examine variations in QOL measurements for the cohort that completed all three surveys. A balanced design was used, in which only patients who completed all three measurements were included in the analysis. Cumulative incidence of chronic GVHD and relapse was also calculated. The competing risk for chronic GVHD was death, whereas the competing risk for relapse was treatmentrelated mortality, defined as death in a patient who had not relapsed.
Results
Between 1996 and 1999, 728 patients underwent HCT. A total of 458 (63%) were sent surveys before transplantation; of these, 320 (44%) responded, with 201 undergoing allogeneic HCT and the remaining 119 undergoing autologous HCT. A total of 234 patients (73%) survived at least 6 months. Of the survivors at 6 months, 197 (84%) returned completed surveys. At 12 months, there were 213 survivors (66%) from the original cohort who had returned baseline surveys. Of these, 175 (82%) returned completed surveys.
Characteristics of the study population are shown in Table 1 . The median age was 47 years, with a range from 19 to 73. There was an equal distribution by sex, and approximately half of the patients reported having a college education. The vast majority (78%) were married or partnered. Most of the patients were white subjects. There was a broad distribution of diagnoses, with the most common being CML (25.6%), non-Hodgkin's lymphoma (21.9%), multiple myeloma (18.6%) and acute myelogenous leukemia (10.9%). A total of 201 (63%) of the patients were scheduled for allogeneic transplantation. Further information about the patient cohort has been previously published. 16 Pre-HCT QOL measurements are shown in Table 2 . The mean MCS score (49.40710.53) was nearly that of the general population, indicating normal mental functioning. In contrast, the mean PCS score was 42.54, nearly 1 s.d. below the population mean of 50. A similar decrement of physical functioning has been observed in chronic medical conditions such as chronic obstructive pulmonary disease 17 and survivors of myocardial infarction. 18 Patients also completed a health rating scale ranging from 0 to 100, with 0 indicating death and 100 indicating perfect health. The mean score was 79.61. Patients' answers to the question 'In general, how is your overall health?' are shown as well. Over half (63.5%) rated their health as excellent or very good before transplantation. Thus, specific deficits in health and functioning were clearly detectable before HCT. Table 3 shows the change in QOL measures in our cohort over time for survivors who completed surveys at all three time points. On the five-point scale rating overall health, there was a 0.51 point drop between baseline and 6 months, which rebounded slightly by 12 months. The mean physical composite score dropped by 1.83 points at 6 months but was slightly better than baseline by 12 months. The mental composite score rose by 2.11 points at 6 months and was higher still at 12 months. The magnitude of these changes was small, indicating that in the cohort as a whole, physical and mental functioning was largely preserved at 6 and 12 months post-HCT for survivors. The analysis was repeated for patients who returned surveys at 0 and 6 months, in Predicting post transplantation quality of life DJ Andorsky et al order to include sicker patients who had died by 12 months. The values and the trends were similar to the analysis at all three time points. Table 4 shows the results of multivariate modeling of QOL outcomes at 6 and 12 months post transplantation, adjusting for type of transplantation procedure, age, disease status, sex, marital status, education, baseline general health status, the pre-transplantation scores on the physical composite score of the SF-36, the mental composite score of the SF-36 and health rating scales. In addition, post transplant clinical events (acute and chronic GVHD, disease relapse) were included as potential predictors. The cumulative incidence of chronic GVHD at 6 months was 18.0% (95% confidence interval (95% CI) 12.1-24.8%) and 36.0% at 12 months (95% CI 28.1-43.9%). The cumulative incidence of relapse at 6 months was 8.8% (95% CI 5.9-12.3%) and 12.8% at 12 months (95% CI 9.3-16.9%). Statistically significant predictors of QOL outcomes are listed.
In general, at 6 months, recovery from transplantation and better social function was correlated with self-reported pre-transplantation overall health and mental health (measured on the SF-36). Better overall health at 6 months was associated with better health pre-transplantation, as measured by the 100-point rating scale, in addition to being unmarried and not having chronic GVHD. Patients were more likely to agree that life was back to normal if they rated their pre-transplantation overall health as excellent or very good, were female or if they had undergone autologous transplantation. Patients who felt that they had put their illness behind them were more likely to have better pre-transplantation mental health (as measured on the SF-36), be female and have undergone autologous transplantation. Patients who felt that they had recovered from their HCT at 6 months were more likely to report better health pre-transplantation and not to have developed acute GVHD. Enjoying normal activities at 6 months was correlated with excellent or very good overall health pre-transplantation, as well as intermediate or poor risk disease. Notably, this was the only QOL outcome for which disease risk was a predictor. Patients who were enjoying socializing with friends and family were more likely to have better pre-transplantation mental health and to have undergone autologous transplantation. At 12 months, baseline mental health and self-reported overall health remained important predictors of recovery. In addition, better physical health (measured by the SF-36) was a significant predictor for four of six outcomes. In particular, a higher PCS before transplantation was associated with agreement with life returning to normal, putting one's illness behind them, enjoying normal activities and enjoying socializing.
We considered the possibility that baseline QOL and disease risk were correlated, and that disease risk was not retained in the model because it was suppressed by the presence of the QOL variables. Therefore, multivariate models for all outcomes were constructed which did not include baseline QOL measurements as independent variables. The variables included were type of transplant, age, disease status, sex, marital status and education. The results were similar to the models that included baseline QOL variables. As in the previous analyses, good risk disease was associated with being less likely to enjoy normal activities at 6 months, but not with any other outcome.
Multivariate proportional hazard analysis was performed to determine independent predictors of survival after transplant. Shorter survival was associated with the occurrence of relapse, allogeneic transplantation, increased age and intermediate or poor risk disease. Pre-transplantation QOL measurements were not significantly correlated with duration of survival.
Discussion
We evaluated the ability of prospectively collected, selfreported QOL data before transplantation, patient and procedural characteristics and post transplantation complications to predict QOL in HCT recipients at 6 and 12 months post transplantation. In general, our results show that post transplantation physical and mental functioning is strongly associated with QOL measured pre-transplantation. Adverse clinical events such as relapse or chronic GVHD were also independent predictors of poor outcome, as has been documented previously. 8, 19, 20 However, even after controlling for these transplantation-related clinical events, pre-transplantation QOL remained a strong independent predictor of post transplantation self-reported recovery, at least through the first year. In contrast, pretransplantation QOL was not associated with overall survival after HCT.
Our data demonstrate that patients were more likely to report recovery from HCT at 6 months if they had better mental functioning or self-rated overall health at baseline. Physical functioning at baseline, as measured by the SF-36, was not a predictor for any of the six outcomes at 6 months. A possible explanation for these findings is that early in the post transplant period, all patients are still suffering the physical effects of the transplantation procedure, and baseline physical health is not a significant determinant of their sense of recovery. By 12 months, patients who entered transplantation with impaired physical functioning might still not feel that they had recovered. In contrast, better mental health at baseline conferred an advantage in perceptions of recovery at both 6 and 12 months.
Although many clinicians may feel that an arduous medical procedure like HCT results in unpredictable transplantation complications that dominate subsequent QOL, the association between pre-and post transplantation QOL was robust in our study. Pre-transplantation scores on objective, validated QOL scales (the SF-36) as well as self-assessment of overall health were strongly associated with post-transplantation QOL of all outcomes that we evaluated. In contrast, disease risk, which is highly predictive of survival, was only an independent predictor for enjoying normal activities at 6 months. Allogeneic transplantation was associated with worse QOL at 6 months, but this association had largely disappeared by 12 months. This is consistent with previous observations that recipients of autologous HCT had a significantly better early QOL with respect to allogeneic recipients, but that by 12 months the QOL outcomes were similar in both groups. 21 Paradoxically, good risk disease was associated with being less likely to be enjoying normal activities at 6 months. We hypothesize that individuals with good risk disease were likely more functional going into transplantation than those with intermediate or poor disease risk, who had been living with their illness and the side effects of treatment for longer periods of time. They may have been more likely to define 'normal' as closer to the level of activity enjoyed by a healthy individual, a goal that is difficult to achieve 6 months after transplantation. In contrast, individuals who have been ill for longer may have adjusted to a lesser level of activity before the transplant, and therefore were more likely to feel that they had returned to their normal level of activity at 6 months.
In contrast to other studies, we found that being unmarried or unpartnered and female were independent predictors of good outcomes. Support of family and friends is typically associated with improved QOL and well-being. 22 In other studies, women report poorer QOL outcomes after HCT. In general, caution should be attached to these findings, as the associations were present for only a few QOL outcomes.
Among patients who survived to 12 months, QOL as measured by the PCS and MCS scales was relatively constant across the pre-and post-HCT period. Even at 6 months post-HCT, 33.8% of patients reported excellent or very good overall health. Thus, although post-HCT QOL was influenced by clinical events and pre-HCT QOL, QOL for the cohort as a whole was well preserved during the first year following transplantation.
We found that pre-HCT QOL was not a significant predictor of survival. This issue has not been examined extensively in HCT, and it contrasts with a growing body of literature in other malignancies, where pre-treatment QOL has been shown to be a predictor of survival in advanced breast cancer, 23 lung cancer, 24, 25 colorectal cancer, 26 melanoma 27 and multiple myeloma, 28 among others. Possible reasons for this might include the following: the high treatment-related morbidity and mortality of HCT in contrast to conventional chemotherapy; the rapidity of relapse and progression of aggressive hematologic malignancy after HCT; that HCT is a curative modality, whereas chemotherapy for metastatic solid tumors is generally not; and that patients may be undergoing HCT before the development of serious impairment as a result of their illness, as in stable-phase CML.
Previous prospective studies have examined the effects of pre-transplantation functioning and QOL factors. A study of 101 HCT recipients indicated that emotional distress at 3 and 12 months post transplantation was correlated with pre-transplantation emotional distress. 29 In another study of 125 patients, general QOL and psychiatric symptoms at 3 years were associated with baseline values of the same measurements. 30 An investigation of psychosocial distress after HCT demonstrated that pre-transplantation distress was highly predictive of post transplantation distress, with the presence of pre-transplantation distress having a positive predictive value of 81%. 31 Several other smaller prospective studies 4, 32, 33 indicate that both physical and psychological health after transplantation is associated with pre-transplantation health. Our study, which was significantly larger than those cited above, emphasizes the important methodologic point that cross-sectional studies evaluating patients only post transplantation might incorrectly attribute observed deficits to the transplantation procedure itself, whereas compromised functioning may have predated HCT.
There are several limitations to our study. Our results look at recovery during the first year after transplantation, whereas previous work has shown that full recovery may take 3-5 years. 20, 34 Further follow-up is needed to determine if pre-transplantation QOL is predictive of QOL several years post transplantation. In addition, precise assessment of disease risk is limited by the heterogeneity of the diagnoses in our cohort. Finally, there may be additional clinical factors that predict posttransplantation QOL that we did not have available for the analysis.
As more patients undergo and survive HCT, focus on ways to improve post transplantation QOL among survivors will become increasingly important. Our results suggest that patients who are at risk for poor post-HCT QOL can be readily identified by simple questions about current QOL before HCT. Interventions to improve post-HCT QOL could then be targeted at this at-risk population.
